Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
$70.16
$0.53(0.67%)
At close: 4:00 PM EST
$70.16
$0.53(0.67%)
Day’s Range― - ―
52-Week Range$54.11 - $93.25
Previous CloseN/A
Volume488.69K
Average Volume (3M)5.14M
Market Cap
$26.58B
Enterprise Value$26.21B
Total Cash (Recent Filing)$3.32B
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)39.0
Beta1.10
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding390,016,270
10 Day Avg. Volume4,770,963
30 Day Avg. Volume5,141,742
Financial Highlights & Ratios
PEG Ratio39.32
Price to Book (P/B)14.97
Price to Sales (P/S)7.80
P/FCF Ratio49.89
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue5.80
Enterprise Value/Gross Profit9.83
Enterprise Value/Ebitda21.44
Forecast
1Y Price Target
$82.54Price Target Upside17.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
International MomentumStronger international revenue performance versus domestic markets suggests growing uptake abroad that can support overall revenue growth as global adoption expands.
Product InnovationManagement highlighted a smaller, longer‑wear glucose sensor with improved accuracy that should enable expansion into new clinical areas and attract additional patients.
Reimbursement ExpansionAnalysts point to potential broader Medicare and favorable international reimbursement decisions that could increase coverage for non‑insulin users and boost adoption.
Bears Say
Competitive PressureDominance by a major competitor in the type two non‑insulin market constrains share gains and increases the risk of slower penetration in that segment.
Guidance And Product Contribution RiskManagement's guidance implies weaker contribution from the Stelo product and revenue growth that may fall short of analyst projections, tempering near‑term upside.
Reliability And ConfidenceA reliability controversy reduced patient and provider confidence, creating a credibility reset that may slow new patient starts and adoption.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $54.11 and its highest was $93.25 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $26.58B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Apr 23, 2026 which is in 69 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Feb 12, 2026. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dexcom have?
Dexcom has 390,016,270 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.68 in its last earnings report, beating expectations of $0.65. Following the earnings report the stock price went down -14.633%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.54 (17.64% Upside)
$82.54 (17.64% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 77%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.34%
12-Months-Change
Fundamentals
Return on Equity
30.63%
Trailing 12-Months
Asset Growth
18.04%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Company Deck
DXCM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational recovery, solid revenue and margin improvement, robust cash generation, and several product and commercialization catalysts (G7 15-day, Smart Basal, Stelo, EHR integration). Management acknowledged prior supply/sensor deployment issues but demonstrated clear remediation and sequential margin recovery. Near-term headwinds include ramp-related OpEx for the Ireland facility, Q1 cadence seasonality, and uncertainty around CMS timing and competitive/payer dynamics, but these are framed as manageable or temporary. Overall the positives (growth, margin expansion, cash, product momentum) materially outweigh the headwinds.View all DXCM earnings summariesDXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
DXCM Stock 12 Month Forecast
Average Price Target
$82.54
▲(17.64% Upside)
Technical Analysis
Ownership Overview
0.48% Insiders
26.49% Mutual Funds
0.52% Other Institutional Investors
39.63% Public Companies and Individual Investors